TMS for PTSD: What the 2026 MeRT Clearance Really Means

MeRT is a newly cleared TMS system used alongside other care for adults with PTSD. One sham-controlled trial supports it, and the evidence applies to that exact system and course.

Direct answer: MeRT is a newly FDA-cleared, prescription TMS system used alongside other care for adults with PTSD. One sham-controlled trial found modestly greater symptom improvement than sham. The evidence applies to this exact system and course. It does not prove that all TMS works for PTSD or that EEG-guided frequency selection adds benefit.

Key points

• FDA cleared MeRT as an adjunct for adults with PTSD on June 3, 2026. “Cleared” is not the same as “approved.”
• The label belongs to the full Wave MeRT System. This includes its software, compatible MagVenture hardware, and treatment plan.
• One 158-person trial favored active MeRT over sham. A full peer-reviewed report was not found by August 20, 2026.
• The trial tested the full package. It did not prove that EEG-guided frequency selection works better than a fixed active frequency.
• Seizure is rare but possible. Hearing protection, implant screening, mood checks, and an emergency plan matter.
• MeRT is an added treatment, not a replacement for trauma-focused therapy, medication, or urgent care when needed.

Zoom

What changed in 2026?

Post-traumatic stress disorder, or PTSD, can follow a terrible event. This may involve death, serious injury, sexual violence, or a threat of these events. Symptoms can include unwanted memories and avoidance. A person may feel on guard, guilty, or unable to sleep. Mood can change too. These are health symptoms, not a failure of will.

On June 3, 2026, the US Food and Drug Administration cleared the Wave Neuroscience MeRT System. It used the 510(k) pathway. Its exact use is as an adjunct for adults with PTSD. Adjunct means it is added to a care plan. It is not labeled as a replacement for therapy, medicine, or other needed care.[1,2]

FDA clearance is not the same as FDA approval. A 510(k) decision means FDA found the device substantially equivalent to a legally marketed predicate for the stated use. FDA also reviewed submitted PTSD clinical evidence for this new claim. The decision does not mean FDA proved MeRT is the best PTSD treatment. It also does not show that MeRT beats trauma-focused therapy.

The device boundary is important. MeRT uses Wave’s MRT-005 software. It works with compatible MagVenture hardware. MagVenture machines have other FDA-cleared uses too. These include some plans for depression and obsessive-compulsive disorder. Owning a MagPro machine alone does not give a clinic the MeRT PTSD setup or label.[1,4]

How does MeRT work?

TMS stands for transcranial magnetic stimulation. A coil rests against the scalp. Brief magnetic pulses make a small electric field. It reaches the outer brain tissue below the coil. No surgery or anesthesia is used. Most people stay awake and go home after a session. A plain-language tour of the machine, the coil, and the settings that define any TMS protocol is in how TMS works and why the details matter.

For MeRT, staff first record brain waves with an eyes-closed EEG. They also record heart rhythm with ECG. The MRT-005 software studies those signals. It then suggests a pulse rate from 8 to 13 times per second. It does not diagnose PTSD. It cannot deliver the pulse by itself.[1]

The clinician maps a motor threshold. This is the lowest output that can reliably activate a motor path. Treatment is then given over the midline dorsomedial prefrontal cortex, or dmPFC. The strength is 80% of that threshold.

Each session has 30 trains. Each train lasts six seconds. There are 54 seconds between trains. The chosen rate gives 1,440 to 2,340 pulses in about 30 minutes. The cleared course is one session a day, five days a week. It lasts 20 to 25 sessions over four to five weeks.[1]

You may hear loud clicks and feel tapping, scalp pressure, or brief facial movement. Proper hearing protection should be used every time.

Why target this part of the brain?

The dmPFC links to networks used for attention, threat, fear learning, arousal, and emotion control. Think of a rail system. The coil reaches one station near the surface. Activity may then change along linked routes. This picture has limits. The coil does not directly or only reach deep areas such as the amygdala.[12]

Several parts of the explanation have different levels of support:

The trial included an early EEG finding. It linked symptom change with a measure of brain-wave timing near the back of the head. A link cannot show that the brain-wave change caused relief. The role of ECG in choosing a useful rate is also unclear.[1]

What the research shows

The key study was NCT02990793. It took place at several sites. People were randomly put in active or sham groups. Both patients and raters were meant to be kept unaware of the group. Sham was a look-alike step made not to give the full treatment. Each person had PTSD confirmed by a clinician. Each also had a PTSD Checklist score of at least 30. Registry records list ages 18 to 65 and symptoms for at least six months.[1,3] The registry also excluded people whose index trauma happened before age 16, people who had taken antipsychotic, benzodiazepine, or anticonvulsant medicines in the prior 30 days, and anyone with past ECT or TMS. Many people with PTSD fit one of those groups, so the result may not transfer to everyone.[3]

The main analysis included all 158 people as assigned. Of these, 77 were in active MeRT and 81 were in sham. Eighty-four percent finished the course.

The main outcome was the PCL-5. This is a 20-item PTSD form filled out by the patient. Active treatment did better than sham. The standardized effect was about -0.32, with p<0.046. The minus sign means lower symptoms favored active treatment. This is often called a small effect.

The planned second outcome was the CAPS-5. This is a clinician interview for PTSD. It also favored active treatment. The standardized effect was about -0.51, with p<0.0006. This is often called a medium effect.[1]

FDA says the active group improved by 27 PCL-5 points from start to end. That is a change within one group. It is not 27 points more than sham. The public FDA summary does not give the raw gap between groups. It also omits each group’s end score and the confidence ranges for the two main effects. This limits an outside review.

FDA says the groups had similar overall counts of new or worse health events. It reports no serious adverse events. The sample was too small to rule out rare harms.

An early follow-up analysis suggested that PCL-5 gains went on for about two to four months. Another after-the-fact analysis found 68.2% remission in the active group at a later visit. The summary does not give the matching sham rate. It also lacks a full table of who stayed in follow-up. These clues are hopeful. They do not prove that the benefit lasts.[1]

As of August 20, 2026, I did not find a full peer-reviewed report of this key trial. The public evidence rests mainly on FDA’s summary and the trial registry. Wave Neuroscience is tied to the sponsor and is the FDA applicant. Another team still needs to repeat the result.[1-3]

How does this fit with older reviews and guidelines?

The sources do not truly clash. They ask different questions at different times. The new trial cuts some doubt about MeRT. It does not erase a key problem in older research. Targets, rates, dose, study groups, and study quality vary widely.[5,6]

Does the “personalized” frequency explain the benefit?

We do not know. Every person in the active group got the full package. This included EEG and ECG analysis, the chosen rate, dmPFC targeting, and the set schedule. The control group got sham. There was no second active group at one fixed rate.

FDA also reports an after-the-fact analysis by pulse count. It found no clear symptom gap among low, medium, and high groups. The low group had only seven people. The groups were not assigned at random by dose. This test cannot prove that rates are equal. It also cannot prove that matching the rate matters.[1]

A careful clinic should explain this limit. Recording brain waves is real. Choosing a rate is part of the cleared process. Yet the evidence does not show that the software fixes each person’s unique brain problem.

What are the safety issues?

Common short-term effects

Headache, scalp pain, facial twitching, and dizziness are common TMS concerns. They are often brief. They may ease after early visits. Tell staff when pain is strong, new, or worse. Ask how they check coil position and keep the set dose while easing pain.[8-10]

Seizure and fainting

A TMS-related seizure is rare, but the risk is not zero. Risk can rise with epilepsy, a brain lesion, stroke, or a major brain injury. Sleep loss can matter. So can alcohol or drug withdrawal, body chemistry problems, or some medicines. Report medicine changes before the next visit.[8-11]

Fainting can include brief jerking. It can look like a seizure. A clinic should know how to stop treatment and protect you from harm. Staff should assess the event and get urgent help when needed.

Hearing and implants

The coil click can worsen ringing in the ears or hearing loss. This risk rises if ear protection is poor. The patient and nearby staff should use well-fitted hearing protection at every visit.[8-10]

Metal and implanted electronics need an exact review. Many devices may matter. Examples include hearing implants, deep-brain stimulators, electrodes, clips, plates, shunts, pacemakers, and pumps. Metal fragments may matter too. Risk depends on the material and location. It also depends on wires, device function, and distance from the coil. Dental fillings and braces are often handled in a different way than metal inside the skull.

Bring the make, model, implant card, and surgery record. The clinic should check the current Wave and MagVenture guides. It should also check the implant maker’s guide. “MRI safe” alone does not answer the TMS question. A pacemaker is not an automatic yes or no.[8,9]

Mood, suicide risk, and thinking

Mania or hypomania seems uncommon, but it matters. Report much less need for sleep or racing thoughts. Also report very fast speech, unusual confidence, anger, or risky acts. People with a bipolar history need careful checks.[8,10]

TMS is not emergency care for a plan to die by suicide. PTSD and thoughts of suicide can change during care. New or worse thoughts need a prompt safety check. This is true even when a TMS course is underway. If you need help today, urgent mental health care: finding the support you need right away explains where to turn.

Standard TMS studies have not shown a lasting drop in overall thinking skills. Still, the public MeRT PTSD summary lacks a set test of memory and focus. Ask the clinic to record any real change. It should not promise that thinking cannot be affected.[1,8]

Pregnancy, age, and brain injury

Small studies of other TMS plans in pregnancy give some comfort. They do not prove that MeRT is safe or works for PTSD in pregnancy. A pregnant patient needs a shared plan with pregnancy and mental health clinicians.[13,14]

The MeRT PTSD label is for adults. The key trial registry lists ages 18 to 65. Do not extend the result to children. There is also a research gap for adults older than 65. The formal label does not set an upper age limit.

PTSD often overlaps with brain injury. A past injury alone does not settle whether TMS fits. The clinician should review how bad the injury was. Brain damage, past seizures, medicines, and current nerve or brain symptoms also matter.

Related TMS guides

• How TMS works: coils, targets, dose, schedule, and FDA status, explained device by device
• TMS for depression: standard 10 Hz, iTBS, H-coil, and accelerated protocols and their evidence
• TMS for OCD: the BrainsWay H7 protocol, symptom provocation, and the pivotal trial
• How PTSD is treated today: what works and what order to try it in
• The future of PTSD treatment: sorting the promising from the premature

Where does MeRT fit in PTSD care?

The strongest guideline support still goes to trauma-focused talk therapies. These include prolonged exposure, cognitive processing therapy, and EMDR. Some people also benefit from medicine. Care for sleep, substance use, pain, or other health needs may help too.[6,7] The order in which these treatments are usually tried is laid out in how PTSD is treated today.

MeRT may be an added option for an adult after a full check. A good plan asks what matters to the person. It looks at what has been tried and how severe symptoms are. It also asks if daily visits are safe and if the clinic can work with the rest of the care team.

What we still do not know

• Whether EEG and ECG matching adds benefit over one fixed active rate.
• The raw symptom gap between groups and its confidence range.
• How well blinding worked and whether hopes changed the results.
• How benefits compare with trauma therapy, medicine, or another active TMS plan.
• How long benefits last and whether added courses help.
• Whether teams not tied to the maker can repeat the result.
• How well the result applies to people who take the medicines the trial excluded.
• Safety and benefit in pregnancy, minors, and adults older than 65.
• Detailed thinking tests and event rates from the key trial.

Questions to ask a TMS clinic

1. Are you offering the exact Wave MeRT System covered by K260402, or a different EEG-guided or MagVenture protocol?
2. How do you confirm the dmPFC target, motor threshold, frequency, intensity, pulse count, and session schedule?
3. Who reviews my medicines, sleep, substance use, seizure risks, bipolar history, and traumatic brain injury?
4. How will you check my implant make, model, material, lead path, and manufacturer instructions?
5. What hearing protection do you provide, and what happens if tinnitus or ear pain starts?
6. How do you track PTSD symptoms, daily function, mood elevation, cognition, and suicide risk?
7. What is your plan for fainting, seizure, worsening symptoms, or another emergency?
8. How will you coordinate MeRT with my therapist, prescriber, primary clinician, or veteran care team?
9. What costs are not covered, and what outcome would lead us to stop, continue, or change the plan?

Frequently asked questions

Was MeRT approved or cleared for PTSD?

It was FDA-cleared through the 510(k) pathway. The label is as an adjunct for adults with PTSD. “Approved” is not the right term for K260402.[1,2]

Is every MagVenture machine now cleared to treat PTSD?

No. The PTSD label belongs to the Wave MeRT System. It uses compatible MagVenture hardware and the cleared plan. MagVenture hardware by itself has other labels.[1,4]

Does MeRT read my thoughts or memories?

No. EEG records electric rhythms at the scalp. It does not decode a trauma memory or show a private thought. FDA says the software uses EEG and ECG data to suggest a pulse rate.[1]

Does the trial prove personalized treatment is better?

No. It shows that the full MeRT package did better than sham in one trial. The study did not test a fixed-rate active group. We do not know the added value of matching the rate.

Can MeRT replace trauma therapy?

It is labeled as an adjunct. Trauma-focused talk therapy still has the strongest support in the VA/DoD guide. Choice should reflect safety, goals, access, past care, and clinical need.[6,7]

Can TMS cause a seizure?

Yes, rarely. Safety checks and dose limits lower risk but cannot make it zero. Tell the clinic about seizures, brain injury, medicines, sleep loss, and alcohol or drug changes.[8-11]

What if I have a pacemaker or metal implant?

Do not assume it is safe or banned. The answer depends on the exact device, material, wires, and place in the body. Maker guidance matters too. Bring the implant card. Ask for a written review before care.[8,9]

How soon should I expect a result?

The studied course lasted four to five weeks. People may improve at different times. Some will not improve. There is not enough evidence to promise a set or lasting result for one person.

A reasonable next step

If you are thinking about MeRT, bring this guide plus your medicine and implant lists. Meet with a licensed clinician who knows PTSD and the exact device. Ask how it would fit with care that already helps. A good visit should cover reasons to start or wait. It should also include a plan if symptoms get worse.

Medical disclaimer: This article is for education. It cannot diagnose PTSD. It cannot decide whether TMS is safe for you or replace care from a trained clinician. Device labels and clinical guidance can change. Ask the clinic to review the current use guide.

Crisis note: If you may act on thoughts of suicide or cannot stay safe, call 911. You can also go to the nearest emergency room. In the United States, call or text 988 for the Suicide & Crisis Lifeline. Veterans and service members may call 988 and press 1. More crisis resources are listed at the end of this page.

References

1. US Food and Drug Administration. 510(k) Summary: Wave Neuroscience MeRT System, K260402. 2026. FDA decision summary
2. US Food and Drug Administration. 510(k) Premarket Notification Database: K260402. 2026. FDA database record
3. ClinicalTrials.gov. Clinical Trial to Evaluate the Safety and Efficacy of MeRT Treatment in Post-Traumatic Stress Disorder, NCT02990793. Trial registry
4. US Food and Drug Administration. 510(k) Summary: MagVenture TMS Therapy System, K251119. 2025. FDA decision summary
5. Brown R, Cherian K, Jones K, Wickham R, Gomez R, Sahlem G. Repetitive transcranial magnetic stimulation for post-traumatic stress disorder in adults. Cochrane Database of Systematic Reviews. 2024;8:CD015040. doi:10.1002/14651858.CD015040.pub2. PMID:39092744. Cochrane evidence page
6. Department of Veterans Affairs and Department of Defense. VA/DoD Clinical Practice Guideline for Management of Posttraumatic Stress Disorder and Acute Stress Disorder. Version 4.0. 2023. Full guideline
7. VA National Center for PTSD. Overview of Psychotherapy for PTSD. Clinical overview
8. Rossi S, Antal A, Bestmann S, et al. Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines. Clinical Neurophysiology. 2021;132(1):269-306. doi:10.1016/j.clinph.2020.10.003. PMID:33243615. PubMed
9. National Institute of Mental Health. Transcranial Magnetic Stimulation Safety and Risk. 2020. NIMH lecture and transcript
10. Kim WS, Paik NJ. Safety Review for Clinical Application of Repetitive Transcranial Magnetic Stimulation. Brain & NeuroRehabilitation. 2021;14(1):e6. doi:10.12786/bn.2021.14.e6. Journal article
11. Lerner AJ, Wassermann EM, Tamir DI. Seizures from transcranial magnetic stimulation 2012-2016: Results of a survey of active laboratories and clinics. Clinical Neurophysiology. 2019;130(8):1409-1416. doi:10.1016/j.clinph.2019.03.016. PMID:31104898. PubMed
12. Kredlow MA, Fenster RJ, Laurent ES, Ressler KJ, Phelps EA. Prefrontal cortex, amygdala, and threat processing: implications for PTSD. Neuropsychopharmacology. 2022;47(1):247-259. doi:10.1038/s41386-021-01155-7. PMID:34545196. PubMed
13. Kim DR, Wang E, McGeehan B, et al. Randomized controlled trial of transcranial magnetic stimulation in pregnant women with major depressive disorder. Brain Stimulation. 2019;12(1):96-102. doi:10.1016/j.brs.2018.09.005. PMID:30249416. PubMed
14. Lee HJ, Kim SM, Kwon JY. Repetitive transcranial magnetic stimulation treatment for peripartum depression: systematic review & meta-analysis. BMC Pregnancy and Childbirth. 2021;21:118. PMID:33563220. doi:10.1186/s12884-021-03600-3. Article

If you or someone you know is in crisis

• Call 911 or go to your nearest emergency room for any life-threatening emergency.
• 988 Suicide & Crisis Lifeline — call or text 988, available 24/7. En español: marque 988 y oprima 2. Veterans: 988 and press 1, or text 838255.
• Crisis Text Line — text HOME to 741741.
• The Trevor Project (crisis support for LGBTQ+ young people) — call 1-866-488-7386, or text START to 678-678.
• National Sexual Assault Hotline (RAINN) — call 1-800-656-HOPE (4673) or text HOPE to 64673; free, confidential, 24/7. Online chat at RAINN.org/hotline.
• National Domestic Violence Hotline — call 1-800-799-SAFE (7233) or text START to 88788; 24/7, help in 200+ languages. Online chat at TheHotline.org. If your phone or computer may be monitored, calling from a safer device is an option.
• Riverside County — Inland SoCal Crisis Helpline 951-686-HELP (4357), 24/7 (Inland SoCal United Way / 211+, in partnership with RUHS-BH); Community Access, Referral, Evaluation and Support (CARES) Line 800-499-3008, 24/7.
• San Bernardino County — Access Unit (Behavioral Health Helpline) 888-743-1478, 24/7; Mobile Crisis/CCRT 800-398-0018 (24/7, all ages) or text 909-420-0560. Arrowhead Regional Medical Center (ARMC) has a dedicated walk-in adolescent psychiatric ER (ages 13–17).
• Children under 13 — call 911 for immediate danger, contact your county's mobile crisis team (they respond to all ages), or go to the nearest pediatric emergency room.
• California Peer-Run Warm Line (non-crisis — someone to talk to) — call or text 1-855-600-WARM (9276); daytime and evening hours, not a 24/7 line.
• NP Fady (non-emergency) — for routine scheduling or questions, call (909) 707-6261. This line is not monitored for emergencies.